How the Latest Data in MDD Can Guide Treatment Decisions:

Slides:

Advertisements

Similar presentations

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

Advertisements

STAR*D Objectives Compare relative efficacy of different treatment options –Goal is REMISSION, not just “response” –Less than half of patients with depression.

Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint

New Horizons for SMA.

Major Depressive Disorder: Latest Clinical Update

Key Issues in Depression: Highlights From APA 2016

Program Overview. Primary Care Approaches to Cognitive Dysfunction in Major Depressive Disorder.

Primary Care Challenges in Depression - To Treat or Refer?

Major Depressive Disorder: Getting the Patient Back to Work

Focus on MDD: Real World Perspectives for Improving Care

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

What Is Major Depressive Disorder (MDD)?

Optimizing Use of Biological Agents in Ulcerative Colitis

Introducing JAK Inhibitors in Rheumatoid Arthritis

From the 2015 Conferences to the Clinic

From Conference to the Clinic

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

PCP Perspectives Clinical Considerations in Hyperkalemia

Advances in Dyslipidemia: What Have We Learned From ACC 2017

What Has Been Tried and What Is True?

nAMD: Switching Therapies - what you need to know

What Would You Do in This Case of MDD?

CDK4/6 Inhibitors in Breast Cancer:

When Patients With Depression Have Cognitive Deficits

A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.

Decision-making in the eRA of Treating to Target

PCSK9 Inhibitors and Cardiovascular Outcomes

Managing Depression is a Team Effort:

A Better Solution For Cancer Patients With VTE?

Drug-Coated Balloons:

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Examining the Latest Evidence in PAH

Expert Debate in MDD.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Program Overview. Major Depressive Disorder: The Challenging Patient and the Goal of Recovery.

Future Directions in Myelofibrosis: Implications of Emerging Approaches.

The Evolving Treatment Landscape in Atopic Dermatitis

Aspirin and Cardioprevention in 2018

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

After the Baby Comes.

A Time for Change for Managing Patients With VTE Who Have Cancer

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Iron Deficiency in Heart Failure

New Trends in Treatment for Major Depressive Disorder

Communicating With Your Patients About Major Depressive Disorder

Elevated Admission Plasma Glucose Following ACS

Reducing Risk for CV Outcomes

The ABCs of Pharmacogenomics in Clinical Practice

What You Need To Know To Effectively Manage Patients With MDD Key Terms (cont)

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Real-World Evidence.

Omega-3s vs Pure EPA in Clinical Practice

PAH Pathways: What Do the Data Tell Us?”

Binge Eating Disorder.

The Glutamate Pathway.

Anemia Explored.

My PAH Patient.

Widening the Options for Major Depressive Disorder

Top Tips in Evidence-Based Care for HFrEF

Treatment Advances for RA

PCSK9 Inhibitors and Real-World Evidence

Characterizing Virological Suppression in Today's Treatment Paradigm

The Power of As-Treated Analyses

Psoriatic Arthritis.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

How the Latest Data in MDD Can Guide Treatment Decisions:

A Look at Cognition and Depressive Symptomatology

Cognitive Performance in Patients With MDD Treated With Vortioxetine Compared With Escitalopram and Venlafaxine Study Design and Participants

Cognitive Performance in Patients With MDD Treated With Vortioxetine Compared With Escitalopram and Venlafaxine Results

Functional Recovery in Patients With MDD -- the Role of Cognitive Symptoms in Clinical Practice Study Design

Functional Recovery in Patients With MDD -- the Role of Cognitive Symptoms in Clinical Practice Results

Functional Recovery in Patients With MDD -- the Role of Cognitive Symptoms in Clinical Practice Conclusions

30-Day Remission Rates in Severe PPD -- Primary and Secondary Endpoints From a Phase 2 Trial of Brexanolone Study Design and Participants

30-Day Remission Rates in Severe PPD -- Primary and Secondary Endpoints From a Phase 2 Trial of Brexanolone Results

Treating Cognitive Dysfunction in MDD

Cognitive Performance and 12-Month Clinical Outcome in FED

Effects of Vortioxetine on Composite Scores Across Objective Cognitive Tests

Effects of Vortioxetine on Composite Scores Across Objective Cognitive Tests: Results

Subjective and Objective Cognitive Side Effects of ECT: A Pilot Study

An Evaluation of Depression Severity, Cognition, Functioning, and Well-Being

Depression Severity and Cognitive Symptoms Are Independent Predictors of Functioning in Patients With MDD

Depression Severity and Cognitive Symptoms Are Independent Predictors of Functioning in Patients With MDD Findings

The Effect of Cognition on the Well-Being of Patients With Major Depression

The Effect of Cognition on the Well-Being of Patients With Major Depression Findings

Key Points From the Studies

A Lively Debate and THINC-it

Debate Topic: What to Do When Patients Have Inadequate Response to First-Line Antidepressants

Key Points of the Debate

THINC-it

THINC-it Quality Survey Results

Adjunctive Strategies in MDD

FORWARD 5 -- a Study of a Sublingual Buprenorphine/Samidorphan Combination

FORWARD 5 -- a Study of a Sublingual Buprenorphine/Samidorphan Combination Study Design

FORWARD 5 -- a Study of a Sublingual Buprenorphine/Samidorphan Combination Results

Efficacy and Safety of Flexibly Dosed Brexpiprazole for the Adjunctive Treatment of MDD

Efficacy and Safety of Flexibly Dosed Brexpiprazole for the Adjunctive Treatment of MDD Study Design

Efficacy and Safety of Flexibly Dosed Brexpiprazole for the Adjunctive Treatment of MDD Results

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)